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Preclinical studies and small clinical trials suggest that glucagon-like peptide 1 (GLP1) may have a
positive effect on ventricular function. Liraglutide is a GLP1-analogue used in the treatment of type 2
diabetes.
LIPER2 is a phase IV, randomised, double-blind, placebo-controlled, parallel-design trial, assessing the
effect of 6 months’ liraglutide 1.8 mg/d on measures of cardiac function and physical performance in
patients with type 2 diabetes.
A total of 30 patients with type 2 diabetes will be included, if their HbA1c is between 7 and 10% while
on oral agents (including metformin if tolerated and not contraindicated), a maximum of 2 intermediate
or long-acting insulin injections per day or a combination of both.
After their baseline examinations, patients are randomised to receive a daily subcutaneous liraglutide
or placebo injection (titrated to 1.8 mg/d if tolerated) for 6 months.
The primary end-point is the maximal oxygen consumption during cycle ergometry at the end of the
study period. Other end-points include distance covered during a 6-min walk test, left ventricular
ejection fraction and other measures of ventricular systolic and diastolic functions assessed by echo-
cardiography, heart rate, blood pressure, pro-brain natriuretic peptide, C-reactive protein, HbA1c, lipids,
apolipoprotein B, body weight and waist girth. Safety end-points include adverse event reporting, blood
count, kidney and liver function, amylase, lipase, electrolytes, calcitonin, CA19.9 and pregnancy test for
fertile women.
At the time of this report, recruitment is still ongoing. Results are expected to be reported in December
2016.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).formance in type 2 diabetes;
peptide 1; DPP4, dipeptidyl
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Inc. This is an open access article u1. Introduction
Glucagon-like peptide 1 (GLP1) analogues have been incorpo-
rated as a treatment possibility for type 2 diabetes (T2D), based on
their insulin-secreting effects and associated moderate weight-lossnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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described. In fact, cardiovascular actions are of major potential in-
terest, since they may have a big impact on patient prognosis.
GLP1 receptors are present both in the heart and in the
autonomous nervous system. GLP1 receptor knock-out mice
show reduced resting heart rate and increased ventricular
thickness [2]. Indeed, in some animal models of dilated cardio-
myopathy and myocardial ischaemia, GLP1 improves left ven-
tricular function [3,4]. Studies in humans are scarce so far and
their results are controversial. Two small, randomised, controlled
trials showed that acute GLP1 infusion prevented post-
angioplasty stunning [5] and improved left ventricular ejection
fraction after dobutamide injection in patients with ischaemic
heart disease [6]. However, these results were not replicated in
non-diabetic subjects with chronic heart failure [7]. A larger trial,
analysing 105 patients undergoing primary percutaneous coro-
nary intervention for an ST-segment elevation acute myocardial
infarction, showed no effects of intravenous exenatide, a GLP1
analogue, on left ventricular ejection fraction at 3 months or on
ﬁnal infarct size [8]. Furthermore, a trial assessing the dipeptidyl
peptidase 4 (DPP4) inhibitor saxagliptin, which delays the
degradation of GLP1, showed an increase in hospital admissions
due to heart failure [9]. This was not the case, however, with the
DPP4 inhibitor sitagliptin [10] or the GLP1 analogue lixisenatide
[11], which were not associated with any changes in the risk of
cardiovascular events.
Thus, some, but not all, short-term studies assessing the effect of
GLP-1 show improved ventricular function in non-diabetic patients
with established heart disease. Although there are currently trials
in progress, studies in patients with T2D receiving chronic treat-
ment with GLP1 analogues are still scarce [4,12,13].
Liraglutide is a GLP1 receptor agonist approved for the treat-
ment of T2D. Its use is associated with an improvement in some
cardiovascular risk markers, such as brain natriuretic peptide,
plasminogen activator inhibitor 1 [14] and fasting [15] and post-
prandial triglyceridaemia [16] and a trial assessing cardiovascular
events is ongoing [13].2. Objectives and purpose
The aim of this trial is to assess the effect of liraglutide, a GLP1
agonist, on clinically relevant measures of myocardial function in
patients with T2D.3. Trial design
Randomised, placebo-controlled, double blind, parallel group,
phase IV trial (see Fig. 1 and Table 1).4. Study population: selection of subjects
A total of 30 subjects will be included for randomisation. They
are identiﬁed and invited to participate in the outpatient clinics at
the Endocrinology Department and at the primary care centres to
which the hospital is the referral centre.4.1. Inclusion criteria
To be included, the patients should have T2D, treated with oral
agents (includingmetformin if tolerated and not contraindicated), a
maximum of 2 intermediate or long acting insulin injections per
day or a combination of both. With this treatment, their HbA1c
should be between 7% and 10%, both included.4.2. Exclusion criteria
The following criteria would preclude patients from partici-
pating: severe renal failure (estimated glomerular ﬁltration rate
<30 ml/min), liver failure (Child-Pugh score > 6 points), present
or planned pregnancy or breastfeeding or inadequate contra-
ception, intolerance or allergy to liraglutide, familial or personal
history of medullary thyroid cancer or type 2 multiple endocrine
neoplasia, personal history of pancreatitis, triglyceride concen-
trations above 500 mg/dl or alcohol intake >40 g/day, known
active malignancy, treatment with GLP1 agonists or DPP4 in-
hibitors in the previous 3 months, known coronary artery disease
with exercise-induced ischaemia, planned revascularisations in
the following 6 months, severe symptoms of heart failure (NYHA
class IV), impossibility to perform a cycle ergometry (osteoar-
thritis or other reasons) or factors potentially interfering with
adherence to treatment or follow-up (according to the in-
vestigator’s criteria).
4.3. Withdrawal of subjects
Participants will be withdrawn from the study at the 3-month
visit, or as soon as the investigator receives notice, in case of
fulﬁllment of any of the discontinuation criteria (see above). If the
patient decides not to participate at any time after randomisation
or is withdrawn from the study, follow-up visits will be attempted
in order to obtain as complete information as possible, for
intention-to-treat analysis and for safety assessment. Although a
lower dropout is expected, power calculation takes into account a
withdrawal rate of up to 25%. Thus, no replacement of withdrawn
subjects is planned.
4.4. Study setting
Regardless of where patients are identiﬁed, study visits take
place at the hospital. Participants are followed at the Endocrinology
Department, whereas study procedures are also performed at the
Cardiology (echocardiography) and Physical Medicine and Reha-
bilitation departments. Lab measurements are performed in the
hospital’s central laboratories.
5. Intervention
5.1. Dose titration and administration
Liraglutide (Victoza®, Novo Nordisk) 1.2e1.8 mg/day will be
given, as a daily, self-adminitered subcutaneous injection using a
pre-ﬁlled injection pen containing 3 ml (18 mg). The aimed dose
will be 1.8 mg/d, but 1.2 mg/d will be accepted if the higher dose is
not tolerated. Participants will administer 0.6 mg/d during the ﬁrst
week, increase to 1.2 mg/d during the second week and to 1.8 mg/
d during the third week. If gastrointestinal side-effects occur, the
highest tolerated dose will be continued throughout the trial. The
samewill be applied for the presence of repeated hypoglycaemia in
the absence of concomitant secretagogue/insulin treatment.
Patients will be assessed at a screening visit, after having
received oral information and having signed a written informed
consent. If they fulﬁll all of the inclusion criteria and none of the
exclusion criteria, a baseline visit will be performed within one
month of the screening visit and randomisation will proceed. Pa-
tients will initiate the assigned treatment and, after safety assess-
ment at 3 months (12e16 weeks), will complete the 6 month
treatment period (26 ± 2 weeks) before ﬁnal assessment. Addi-
tional telephone contact will evaluate the need for treatment
adjustment within the two weeks following treatment initiation.
Fig. 1. Visit outline.
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Patients will be allowed to use any oral agents prescribed from
the beginning of the trial, one being metformin (if well tolerated
and not contraindicated). Patients should not receive DPP4 in-
hibitors or GLP1 agonists (liraglutide, exenatide) in the 3 months
prior to randomisation or throughout the duration of the trial.
All patients will be instructed regarding lifestyle measures to
optimise glycaemic control and, if already treated with insulin, on
how to modify their insulin dose during the trial. Participants are
warned about the possibility of hypoglycaemia at the start of the
new treatment, especially if HbA1c is already close to 7%. In case of
hypoglycaemia (or risk of hypoglycaemia, according to the in-
vestigator’s criteria), the insulin or sulphonylurea dose may be
reduced.
5.3. Rescue medication
In patients with an HbA1c above 8% at the 3-month visit despite
adequate lifestyle measures, one dose of insulin may be started (at
0.1e0.2 ui/Kg, and adjusted to achieve morning/pre-dinner gly-
caemic concentrations between 70 and 130 mg/dl) in those not
receiving insulin already. In those participants receiving insulin
treatment already, its dose will be adjusted to achieve the
mentioned glycaemic target. An additional intermediate or long-
acting insulin injection may be prescribed if deemed necessary in
those patients treated with one injection only. Concomitant oral
agents will not be modiﬁed during the duration of the trial unless
hypoglycaemia occurs.
5.4. Drug accountability
At each follow-up visit, participants will be asked about
compliance with study drug and concomitant treatments. In
addition, unused, half-full and empty injection pens will beTable 1
Visit description.
Visit V0 V1 V2
Time (weeks, range) 2 (5e(1)) 1 (3e0) 0
Clinical history X
Physical examination X
EuroQoL X
Glycaemic control X X
Lab tests X
Pregnancy test X
Echocardiography X
6-min walking test X
Cycle ergometry X
Physical activity Holter X
Randomisation X
Drug dispensation X
Recovery of unused/used drug
Assessment of adverse events
Telephone follow-upcollected, counted and kept at the Hospital for monitoring and
thereafter destroyed following standard procedures.
6. Outcomes
6.1. Primary end-point
The primary end-point will be ﬁtness, or physical performance,
deﬁned as the maximal oxygen consumption (VO2max; Breeze
Suite 6.4, Medgraphics, Medical Graphics Corporation, Saint Paul,
MN, USA) during a cycle ergometer test (Ergoselect, Ergoline, Bitz,
Germany) performed at the end of the study. An incremental pro-
tocol is used, where the ﬁrst 3 min are performed without resis-
tance and the latter is then increased by 10e20W/minute (adjusted
according to weight, height, age and ethnicity). The total duration
of the test rarely exceeds 10e12 min. Before the test is started, the
procedure is described in detail and participants sign written
informed consent. Cardiorespiratory ﬁtness is determined during
cycle ergometry using respiratory gas exchange analysis, which
involves the direct, non-invasive measurement of ventilation and
expired oxygen and carbon dioxide. It provides the most accurate
and reproducible quantiﬁcation of cardiorespiratory ﬁtness, a
grading of the etiology and severity of impairment, and an objective
assessment of the response to intervention. Ergometry and VO2
max measurement are performed according to international
guidelines [17]. Calibration is performed with a 3 L air-syringe,
adjusting for ambient temperature and atmospheric pressure.
Maximal exertion ergometry (HR > 85% theoretical maximum and
RER > 1.10) is attempted and participants are encouraged to
perform as well as they can.
All patients perform the test at the Rehabilitation and Physical
Medicine Department, in the morning, on the same ergometre and
supervised by the same staff (GM, CM) at baseline and at the end of
the study. A neoprene mask is used as interface, tightly adjusted to
the participant’s face, to avoid air leakage. If the patient is feelingV2aþb V3 V4 V5
þ1, þ2 þ14 (12e16) þ25 (24e26) þ26 (25e28)
X
X
X X
X X
X X
X
X
X
X
X
X X
X X X
X
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treadmill ergometry, on cycle ergometry, power (watt) and VO2
maxmeasurements are direct, rather than estimated. Both tests are
performed with the same resistance scheme and results are
referred to theoretical standards (based on weight, height, age and
ethnicity). Thus, the theoretical standards may change during the
study if the participant’s weight changes.
6.2. Secondary end-points
Secondary endpoints include additional ﬁtness-related vari-
ables, to be recorded during the cycle ergometer test (blood pres-
sure, pulse oxymetry, heart rate response, perceived exertion
during exercise (Borg’s scale) as well as time to exhaustion,
anaerobic threshold (absolute and relative to VO2max), maximal
work load (watt), breakpoint of ventilatory equivalent of oxygen
(VE/VO2), breakpoint of ventilatory equivalent of carbon dioxide
(VE/VCO2), respiratory exchange ratio (RER), 1 and 3 min heart rate
recovery and clinical and electrocardiographic ischaemia (Car-
dioPerfect, Welch Allyn, Skaneateles Falls, NY, USA). We also
determine absolute values of peak oxygen pulse (VO2/HR) and the
pattern of change of the values (early plateau, followed by decline
or continuously ascending).
A 6 min walking test is performed following international
guidelines [18] and the following variables are registered: distance
covered, blood pressure, pulse oxymetry, heart rate response and
perceived exertion.
Transthoracic echocardiograpy is carried out according to in-
ternational guidelines [19] and the following parameters are
assessed: left ventricular ejection fraction, systolic angular speed
with tissular doppler image, myocardial performance index and
diastolic function, classiﬁed according to international echocardi-
ography recommendations [20].
Glycaemic control is assessed using HbA1c, measured by HPLC,
using a NGSP/DCCT-based standard, and examining the patients’
glucose registers, as well as questioning them about hypoglycaemic
episodes (see below), daily insulin dose and other concomitant
medication. Endogenous insulin production is assessed by fasting
C-Peptide (chemoluminiscence). Anthropometric parameters
(height, weight, waist girth) are also recorded. Other laboratory
measurements are performed using routine, automatic methods.
They include: lipids, apolipoprotein B, C-reactive protein (turbi-
dimetry) and pro-brain natriuretic peptide (NT-pro-BNP). The
hospital’s laboratory has been certiﬁed by the Spanish Society of
Clinical Biochemistry and Molecular Pathology (SEQC, Barcelona,
Spain).
Quality of life is assessed using a validated questionnaire,
available in Spanish, and its Visual Analogue Scale (Spain (Spanish)
v.2 © 2009. EQ-5D-5L, EuroQoL Foundation, Rotterdam, The
Netherlands).
Spontaneous physical activity is recorded using a physical ac-
tivity Holter (SenseWear Pro, BodyMedia, Pittsburgh, PA, USA) for
three days: number of steps, time spent on exercise >3 METs and
energy consumption (Calories) per 24 h are registered.
The primary and secondary endpoints will be assessed at
baseline and at the end of the study (6 months), except those
related to glucose control, which will be evaluated at the 3 months
visit, too.
6.3. Safety end-points
The safety end-points include adverse event (AE) reporting,
blood count, liver and kidney function, electrolytes, lipase, amylase,
CA19.9 and calcitonin. A general physical examination is performed
at baseline and at the end of the study. A pregnancy test isperformed on all women with childbearing potential before ran-
domisation and during follow-up (visits 3 and 5). Pregnancy will
not be considered an adverse event but study drug will be inter-
rupted and the patient closely monitored until 6 months after de-
livery. Pregnancies will be reported to the local EC, the Spanish
National Drug Agency and the manufacturer.
Patients are speciﬁcally asked at each visit about AEs and each
one is registered in a standardised manner, where severity (mild,
moderate, severe), outcome, potential causality relationship (un-
likely, possible, probable) and action taken are recorded. In addi-
tion, at baseline and at each follow-up visit, hypoglycaemic events
are assessed and recorded as referred by the patients or recorded
in their diary. Hypoglycaemia is deﬁned as capillary blood glucose
concentrations below 60 mg/dl, with or without symptoms or
symptoms suggestive of hypoglycaemia, which resolve after
treatment, even if no blood glucose measurement is performed.
Severe hypoglycaemia is identiﬁed separately and deﬁned as an
episode of hypoglycaemia, which needs external assistance to be
solved.
In addition, at the end of the study, an endoscopic ultrasound is
offered to the patients, in order to assess pancreatic architecture. A
separate, standard consent form is provided and signed before the
examination.7. Statistical considerations
7.1. Sample size
Based on a previous study in patients with T2D performing an
exercise test on a treadmill [21], we assumed a mean between
29.5 and 37.7 ml/kg*min and a standard deviation of 3.5 ml/
kg*min in VO2max, similar in both intervention groups. Training
programmes in older men increase VO2 max by 16e45% [22],
which would correspond to an absolute change of 5e14 ml/
kg*min, approximately. Including 15 patients per group would
allow the detection of a difference between groups of 5 ml/
kg*min in VO2max with 98% power and bilateral alfa of 5%. Even
in the event of an unexpectedly high drop-out rate of 25%, the
power to detect this difference between groups would be of 90%.
Given the high correlation between cycle and treadmill ergo-
metry [23] and the lack of sufﬁcient data on cycle ergometry in
T2D, we assumed that these calculations are applicable to the
described trial.7.2. Statistical analyses
Analysis will be performed on an intention-to-treat and per-
protocol basis. The intention-to-treat population will be deﬁned
as those patients who have been randomised, regardless of treat-
ment adherence or follow-up. In the absence of complete follow-up
data, the “last observation carry-forwardmethod”will be used. This
should be conservative enough, since, for most of the measure-
ments, only baseline and 6-month results will be available. In case
of missing follow-up, baseline measurements would be carried
over. For “per protocol” analysis, only those subjects who have
completed treatment and follow-up will be included. Variables will
be expressed as percentages (qualitative), as mean (SD) (quantita-
tive, Gaussian distribution) or as median (range) (quantitative, non-
Gaussian distribution). Comparison between the intervention and
placebo groups will be performed using chi-squared (qualitative
data), Student’s T test (quantitative, Gaussian distribution) and
Mann-Whitney’s U (quantitative, non-Gaussian). ANCOVA analysis
will be performed to adjust for age, gender, smoking and baseline
VO2max.
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Both the active drug and the identically-looking placebo are
provided by the manufacturer in pre-ﬁlled injection pens. Neither
the patient nor the investigators are aware of the content of the
injections. The manufacturer provided the computer-generated
randomisation code and sent it to the unblinded pharmacist,
who arranges study drug dispensation according to random-
isation. A sealed, opaque envelope with the allocation sequence is
kept in the investigator ﬁle, for use in case of emergency. Patients
are enrolled and assigned consecutive numbers by the in-
vestigators and thereafter sent to the hospital pharmacy for
treatment allocation, which is performed by sequentially
revealing the assigned treatment kit number. The randomisation
number is unique for each patient and constant for the duration of
the trial.9. Ethics considerations and compliance with guidelines and
regulations
The study has been approved by the Ethics Committee of the
Complejo Hospitalario Universitario Insular Materno Infantil and
by the Spanish Medical Agency. Before inclusion, patients receive
oral and written information about the study and a written,
informed consent document is signed by each participant. The trial
will be performed in compliance with the protocol and in accor-
dance with the Declaration of Helsinki and the International Con-
ference on Harmonisation of Good Clinical Practice.
Data accuracy and compliance with the protocol, with Good
Clinical Practice International Guidelines and with national regu-
lations is assessed by external, qualiﬁed staff from CRAnarias SL, Las
Palmas de Gran Canaria, Spain. Monitoring includes personal visits
and telephone communication. The monitoring staff have access to
the case report forms and to the source data.10. Funding
The LIPER2 trial was approved and funded by Novo Nordisk,
Bagsvaerd, Denmark. The investigators designed and are con-
ducting the study, will perform all study analyses and have written
and are responsible for the contents of this manuscript.
The manufacturer will not interfere with collection, analysis,
interpretation, writing, or publication of data. The principal inves-
tigator will have full access to all the data and the ﬁnal re-
sponsibility for the decision to submit for publication. The results of
the trial will be published regardless of whether they are positive or
negative.11. Study status
The ﬁrst patient was recruited in June 2013. At the time of this
report, 35 participants have been screened, 11 have been excluded
after screening and 24 have been randomised. A total of 22 have
ﬁnished the study. The last visit of the last patient is planned for
August 2016 and the report of the results is expected by December
2016.12. Discussion
Patients with T2D have an increased risk of cardiovascular dis-
ease, which is the main cause of death in this population. The
identiﬁcation of agents that not only lower blood glucose, but also
improve cardiovascular prognosis, would be of great interest.13. Conclusions
The LIPER2 trial assesses the effect of 6 months’ treatment with
liraglutide, as compared with placebo, on measures of physical
performance and ventricular function in patients with T2D who
have a baseline HbA1c between 7 and 10%.
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